These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12727938)

  • 1. Clinical review 158: Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer.
    Braga-Basaria M; Ringel MD
    J Clin Endocrinol Metab; 2003 May; 88(5):1947-60. PubMed ID: 12727938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy in radioiodine refractory thyroid cancer.
    Pacini F; Brilli L; Marchisotta S
    Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):520-5. PubMed ID: 19910905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current role of targeted therapies to induce radioiodine uptake in thyroid cancer.
    Fröhlich E; Wahl R
    Cancer Treat Rev; 2014 Jun; 40(5):665-74. PubMed ID: 24485648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic thyroid cancer unresponsive to conventional therapies: novel management approaches through translational clinical research.
    Sarlis NJ
    Curr Drug Targets Immune Endocr Metabol Disord; 2001 Aug; 1(2):103-15. PubMed ID: 12476792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era.
    Capdevila J; Argiles G; Rodriguez-Frexinos V; Nuñez I; Tabernero J
    Discov Med; 2010 Feb; 9(45):153-62. PubMed ID: 20193642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target therapies for radioiodine refractory advanced thyroid tumors.
    Schlumberger M
    J Endocrinol Invest; 2012; 35(6 Suppl):40-4. PubMed ID: 23014073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Differentiated thyroid cancer -- 2009].
    Konrády A
    Orv Hetil; 2011 Jan; 152(5):163-70. PubMed ID: 21247857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approach to the thyroid cancer patient with extracervical metastases.
    Haugen BR; Kane MA
    J Clin Endocrinol Metab; 2010 Mar; 95(3):987-93. PubMed ID: 20203334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid cancer molecular signaling pathways and use of targeted therapy.
    Kundra P; Burman KD
    Endocrinol Metab Clin North Am; 2007 Sep; 36(3):839-53, viii. PubMed ID: 17673131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on thyroid cancer treatment.
    Regalbuto C; Frasca F; Pellegriti G; Malandrino P; Marturano I; Di Carlo I; Pezzino V
    Future Oncol; 2012 Oct; 8(10):1331-48. PubMed ID: 23130931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyrotropin in the development and management of differentiated thyroid cancer.
    McLeod DS
    Endocrinol Metab Clin North Am; 2014 Jun; 43(2):367-83. PubMed ID: 24891167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redifferentiating agents in non-radioiodine avid cancer.
    Seregni E; Vellani C; Castellani MR; Maccauro M; Pallotti F; Scaramellini G; Guzzo M; Greco A
    Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):513-9. PubMed ID: 19910904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carcinogenesis and therapeutic strategies in thyroid cancer.
    Liu ZM; Wu TT; van Hasselt CA; Chen GG
    Curr Drug Targets; 2010 Jun; 11(6):716-32. PubMed ID: 20298151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical therapy for advanced forms of thyroid cancer.
    Rajhbeharrysingh U; Taylor M; Milas M
    Surg Clin North Am; 2014 Jun; 94(3):541-71. PubMed ID: 24857576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioiodine therapy and age at menopause in patients with thyroid cancer.
    Rosario PW; Fagundes TA; Fagundes AV; Barraso AL; Rezende LL; Padrao EL; Guimaraes VC; Purisch S
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):225-6. PubMed ID: 16430725
    [No Abstract]   [Full Text] [Related]  

  • 18. Radioiodine and radiotherapy in the management of thyroid cancers.
    Simpson WJ
    Otolaryngol Clin North Am; 1990 Jun; 23(3):509-21. PubMed ID: 1694984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioiodine therapy for thyroid cancer in the era of risk stratification and alternative targeted therapies.
    Pryma DA; Mandel SJ
    J Nucl Med; 2014 Sep; 55(9):1485-91. PubMed ID: 25134528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical guidance for radioiodine refractory differentiated thyroid cancer.
    Gild ML; Topliss DJ; Learoyd D; Parnis F; Tie J; Hughes B; Walsh JP; McLeod DSA; Clifton-Bligh RJ; Robinson BG
    Clin Endocrinol (Oxf); 2018 Apr; 88(4):529-537. PubMed ID: 29095527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.